The virus that causes tick-borne encephalitis appears to trick the immune system, misdirecting it into producing inferior antibodies. But new research shows some people produce more potent antibodies, providing hope for treatment.

A new study using human genetics suggests researchers should prioritize clinical trials of drugs that target two proteins to manage COVID-19 in its early stages. Based on their analyses, the researchers call for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2. The goal is to identify existing drugs, either FDA-approved or in clinical development for other conditions, that can be repurposed for the early management of COVID-19.

A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.

A new study continues to support a growing body of evidence that aluminum contributes to the pathogenesis of Alzheimer's disease (AD). Researchers found aluminum co-located with phosphorylated tau protein, which is an early initiator of AD.

Psychosocial stress - typically resulting from difficulty coping with challenging environments - may work synergistically to put women at significantly higher risk of developing coronary heart disease, according to a new study.